Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 6/2013

01-11-2013 | Original Article

Application of the fracture risk assessment tool (FRAX®) and determination of suitable cut-off values during primary screening in specific health check-ups in Japan

Authors: Shinichi Nakatoh, Yuki Takemaru

Published in: Journal of Bone and Mineral Metabolism | Issue 6/2013

Login to get access

Abstract

Specific health check-ups, which do not include osteoporosis screening, are conducted more frequently than periodic osteoporosis screening in Japan. In this study, we investigated the usefulness of the fracture risk assessment tool (FRAX®) during specific health check-ups, evaluated the variations in its usefulness for 2 consecutive years, and determined FRAX® cut-off values for osteoporosis screening. FRAX® questionnaires were distributed to subjects who underwent specific health check-ups in 2009 and 2010 at Asahi-machi. Subjects who exhibited FRAX® cut-off values of ≥10 % were advised to be screened at a medical institution. Bone mineral densities (BMDs) were measured in 201 subjects in 2009 and 105 subjects in 2010 after specific health check-ups, and treatment was initiated for 79 subjects in 2009 and 24 subjects in 2010. The number of subjects examined and the rate of treatment initiation following specific health check-ups were higher than those in subjects following periodic osteoporosis screening in 2009. However, the number and the rate following specific health check-ups dropped in 2010. According to receiver operating characteristic curves analyses, the sensitivity and specificity of FRAX® to determine osteoporosis treatment were highest when the cut-off values were 8 % for men and 10.5 % for women. In conclusion, the combination of FRAX® and specific health check-ups was more useful than periodic osteoporosis screening to narrow down the subjects and to motivate them to seek follow-up. Cut-off values for specific health check-up using FRAX® should be approximately 8 % for men and 10.5 % for women
Literature
1.
go back to reference Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, Endo N, Nakano T, Itoi E, Kita K, Yamamoto N, Aoyagi K, Yamazaki K (2010) Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 15:737–745PubMedCrossRef Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, Endo N, Nakano T, Itoi E, Kita K, Yamamoto N, Aoyagi K, Yamazaki K (2010) Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 15:737–745PubMedCrossRef
2.
go back to reference Yamauchi H, Sasaki T, Hosoi T (2011) Present situation of medical screening system for osteoporosis. Nihon Rinsho 69:1300–1304 (in Japanese)PubMed Yamauchi H, Sasaki T, Hosoi T (2011) Present situation of medical screening system for osteoporosis. Nihon Rinsho 69:1300–1304 (in Japanese)PubMed
4.
go back to reference Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzzoli R (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399–428PubMedCrossRef
5.
go back to reference Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–435PubMedCrossRef Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Oden A, Johansson H, Kanis JA (2008) Development and application of a Japanese model of WHO fracture risk assessment tool (FRAX™). Osteoporos Int 19:429–435PubMedCrossRef
6.
go back to reference Silverman SL, Calderon AD (2010) The utility and limitation of FRAX: A US perspective. Curr Osteoporos Rep 8:192–197PubMedCrossRef Silverman SL, Calderon AD (2010) The utility and limitation of FRAX: A US perspective. Curr Osteoporos Rep 8:192–197PubMedCrossRef
7.
go back to reference Nakatoh S (2009) Utility and problems of FRAX in clinical use. Clin Calcium 19:1756–1767 (in Japanese)PubMed Nakatoh S (2009) Utility and problems of FRAX in clinical use. Clin Calcium 19:1756–1767 (in Japanese)PubMed
8.
go back to reference Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:S407–S413PubMedCrossRef Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21:S407–S413PubMedCrossRef
9.
go back to reference Siris ES, Baim S, Nattiv A (2010) Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and old men. Postgrad Med 122:82–90PubMedCrossRef Siris ES, Baim S, Nattiv A (2010) Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and old men. Postgrad Med 122:82–90PubMedCrossRef
10.
go back to reference Orimo H (2006) Japanese guideline for prevention and treatment of osteoporosis. Life Sci (in Japanese) Orimo H (2006) Japanese guideline for prevention and treatment of osteoporosis. Life Sci (in Japanese)
11.
go back to reference Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 version. J Bone Miner Metab 19:331–337PubMedCrossRef Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H (2001) Diagnostic criteria for primary osteoporosis: year 2000 version. J Bone Miner Metab 19:331–337PubMedCrossRef
12.
go back to reference Yamauchi H, Fukunaga M, Nishikawa A, Orimo H (2010) Changes in distribution of bone densitometry equipment from 1996 to 2006 in Japan. J Bone Miner Metab 28:60–67PubMedCrossRef Yamauchi H, Fukunaga M, Nishikawa A, Orimo H (2010) Changes in distribution of bone densitometry equipment from 1996 to 2006 in Japan. J Bone Miner Metab 28:60–67PubMedCrossRef
13.
go back to reference Nelson HD, Helfand M, Woolf SH, Allan JD (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:529–541PubMedCrossRef Nelson HD, Helfand M, Woolf SH, Allan JD (2002) Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 137:529–541PubMedCrossRef
14.
go back to reference Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R (2010) Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 153:99–111PubMedCrossRef Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R (2010) Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 153:99–111PubMedCrossRef
15.
go back to reference Yamauchi H, Nishikawa A, Orimo H (2007) The present conditions of osteoporosis detection survey in Japan. Osteoporos Jpn 15:645–655 (in Japanese) Yamauchi H, Nishikawa A, Orimo H (2007) The present conditions of osteoporosis detection survey in Japan. Osteoporos Jpn 15:645–655 (in Japanese)
Metadata
Title
Application of the fracture risk assessment tool (FRAX®) and determination of suitable cut-off values during primary screening in specific health check-ups in Japan
Authors
Shinichi Nakatoh
Yuki Takemaru
Publication date
01-11-2013
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 6/2013
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-013-0457-6

Other articles of this Issue 6/2013

Journal of Bone and Mineral Metabolism 6/2013 Go to the issue

List of Reviewers 2012-2013

LIST OF REVIEWERS 2012–2013

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.